- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Call
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Mark Eaton
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sant-Rayn Pasricha
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A new regulator of 'stemness' to create dendritic cell factories for immunotherapy
- Advanced imaging interrogation of pathogen induced NETosis
- Cancer driver deserts
- Cryo-electron microscopy of Wnt signalling complexes
- Deciphering the heterogeneity of breast cancer at the epigenetic and genetic levels
- Developing drugs to block malaria transmission
- Developing new computational tools for CRISPR genomics to advance cancer research
- Developing novel antibody-based methods for regulating apoptotic cell death
- Discovering novel paradigms to cure viral and bacterial infections
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Do membrane forces govern assembly of the deadly apoptotic pore?
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- E3 ubiquitin ligases in neurodegeneration, autoinflammation and cancer
- Engineering improved CAR-T cell therapies
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- Genomic rearrangement detection with third generation sequencing technology
- How does DNA damage shape disease susceptibility over a lifetime?
- How does DNA hypermutation shape the development of solid tumours?
- How platelets prevent neonatal stroke
- Human lung protective immunity to tuberculosis
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of dysregulated Tom40 in neurodegeneration
- Investigating the role of mutant p53 in cancer
- Lupus: proteasome inhibitors and inflammation
- Machine learning methods for somatic genome rearrangement detection
- Malaria: going bananas for sex
- Measurements of malaria parasite and erythrocyte membrane interactions using cutting-edge microscopy
- Measuring susceptibility of cancer cells to BH3-mimetics
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Mutational signatures of structural variation
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Revealing the epigenetic origins of immune disease
- Reversing antimalarial resistance in human malaria parasites
- Structural and functional analysis of DNA repair complexes
- Targeting human infective coronaviruses using alpaca antibodies
- Towards targeting altered glial biology in high-grade brain cancers
- Uncovering the real impact of persistent malaria infections
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding how malaria parasites sabotage acquisition of immunity
- Understanding malaria infection dynamics
- Understanding the mechanism of type I cytokine receptor activation
- Unveiling the heterogeneity of small cell lung cancer
- Using alpaca antibodies to understand malaria invasion and transmission
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to cross the blood brain barrier for drug delivery
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
c-FIND FAQs
c-FIND is a fast and accurate new test that has the potential to detect multiple viral, bacterial or fungal infections within minutes.
The test is being developed into a portable, point-of-care diagnostic device that could transform Australia’s ability to provide targeted clinical care and respond to pandemics and biosecurity threats.
Is c-FIND available now?
The test is currently being developed into a portable, point-of-care diagnostic that could be ready for implementation in Australian healthcare settings within 24 months.
What is a point-of-care test?
Point-of-care testing is when patient testing and diagnosis can be performed on the spot by a healthcare professional, as opposed to a sample being taken and sent away to another location for assessment.
What’s involved in taking the test?
Once fully developed, operation of the c-FIND diagnostic device would involve taking a blood, mucus or saliva sample from a patient and – with minimal preparation – applying this to a small cartridge. The cartridge would then be inserted into the device to rapidly screen for as many as eight different viral, fungal or bacterial organisms at a time.
How does it work?
c-FIND is based on CRISPR technology. It uses Cas enzymes combined with ‘bait’ RNA molecules that are designed to detect the genome of a pathogen (disease-causing microbes). If the pathogen’s genome is present in a sample, it will bind to the bait. This combination of the genome plus bait will then be cut by the Cas enzyme, which then goes on to cleave a fluorescent reporter sequence causing the emission of light.
Simply put, the use of CRISPR as a genomic detection tool allows even the faintest genetic traces of disease-causing microbes to be detected causing the device to light up when an infection is identified.
What are the limitations of current tests?
Current tests are resource intensive and more expensive to run. This is because they require highly trained staff and a centralised laboratory to process samples. The need to send samples away to another location means it usually takes days or even weeks to return a result.
In clinical care settings, there are many conditions for which tests do not exist, are sub-optimal or take time to process. Delays in accurate diagnosis can lead to patients having expensive drug treatments, or invasive procedures that may not have been necessary, as well as an increased chance of disease transmission.
What are the benefits of c-FIND?
Development of the c-FIND diagnostic device would mean the introduction of a fast, reliable, easy to use, portable test that would be able to screen for more than one infection at a time, be easily adapted to screen for new and emerging infections and be much less expensive to run than existing tests
How is c-FIND funded?
Following a successful bid for $1M in funding from the Australian Government Medical Research Future Fund (MRFF) Frontiers program, the c-FIND research team is applying for up to $100M over five years through the MRFF Stage 2 funding process.
Further support would help to take the c-FIND program of research to the next level and would enable the launch of 13 clinical trials to rigorously assess implementation of the c-FIND diagnostic device in Australian healthcare settings with urgent, unmet diagnostic needs.
Who developed c-FIND?
c-FIND was developed by Walter and Eliza Hall Institute medical researchers who are world-leaders in infectious diseases research and CRISPR technology, in collaboration with Melbourne Health, Murdoch Children’s Research Institute, Peter MacCallum Cancer Centre, The Royal Children’s Hospital, University of Melbourne, as well as industry partner and local biomedical technology company, Axxin Pty Ltd.
What tests are currently used for COVID-19?
The most common tests for COVID-19 are DNA amplification tests such as PCR and antibody detection tests. PCR tests generally only look for one disease at a time, are resource intensive and take days to return a result. Antibody detection tests can only show if a person has encountered SARS-CoV-2 in the past and cannot detect whether a person is currently infected.
Are there other CRISPR tests out there?
All current CRISPR disease detection tests are in the proof-of-concept phase. No other programs using CRISPR technology in this way have the extensive clinical networks to support the implementation of the test.
Are there tests like c-FIND overseas?
Outside Australia, there are several other projects using CRISPR technology to develop diagnostic tests for COVID-19. However, c-FIND is distinctive as it will be multiplexed which means it can screen for more than one infection at a time.
How would c-FIND improve Australian clinical care?
Equipping clinicians with c-FIND to diagnose infections accurately and even determine antimicrobial resistance on the spot could be a game-changer for improving targeted patient care. For example, in cancer care, the introduction of c-FIND could save high-risk patients from waiting days or weeks for test results to come back whilst having expensive drug treatments, or invasive procedures that may not have been necessary.
How would c-FIND improve Australia’s response to current and future pandemics?
c-FIND could prevent disease spread and save lives by screening for life-threatening diseases, including SARS-CoV-2, enabling people who are infected to be identified, isolated and treated. The ability to obtain an accurate diagnosis in a short period of time is critical to the control of future pandemics.
For example, c-FIND devices could be used in Australian airports, seaports and other points of entry for communicable diseases; in hospitals and clinics to assist with patient admissions, allowing patients to start or continue their required treatment or procedure without disruption; at aged care facilities preventing outbreaks and enabling residents to see their loved ones; and at GP and fever clinics to avoid patient congestion and community transmission.
For further information
- Media release: New c-FIND test accurately diagnoses infection in minutes